Your browser is no longer supported. Please, upgrade your browser.
PPD, Inc.
Index- P/E225.71 EPS (ttm)0.15 Insider Own0.30% Shs Outstand348.58M Perf Week-0.86%
Market Cap11.75B Forward P/E20.95 EPS next Y1.66 Insider Trans-98.35% Shs Float158.64M Perf Month0.09%
Income53.80M PEG13.11 EPS next Q0.31 Inst Own77.10% Short Float2.70% Perf Quarter1.19%
Sales4.36B P/S2.69 EPS this Y-43.50% Inst Trans25.15% Short Ratio4.54 Perf Half Y0.75%
Book/sh-3.06 P/B- EPS next Y17.16% ROA1.10% Target Price41.93 Perf Year19.82%
Cash/sh2.05 P/C16.95 EPS next 5Y17.22% ROE-3.40% 52W Range10.61 - 38.76 Perf YTD1.58%
Dividend- P/FCF39.85 EPS past 5Y- ROI14.10% 52W High-10.32% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin39.50% 52W Low227.62% ATR1.46
Employees23000 Current Ratio1.10 Sales Q/Q1.40% Oper. Margin8.50% RSI (14)45.63 Volatility4.75% 3.75%
OptionableYes Debt/Eq- EPS Q/Q-140.80% Profit Margin1.50% Rel Volume1.66 Prev Close33.54
ShortableYes LT Debt/Eq- EarningsFeb 24 BMO Payout0.00% Avg Volume943.42K Price34.76
Recom1.70 SMA20-3.59% SMA50-1.66% SMA2005.92% Volume1,554,093 Change3.64%
Mar-03-21Initiated Barclays Overweight $42
Oct-12-20Initiated Truist Buy
Jun-04-20Initiated KeyBanc Capital Markets Overweight $35
Mar-23-20Upgrade Jefferies Hold → Buy $30.50 → $20
Mar-02-20Initiated William Blair Outperform
Mar-02-20Initiated UBS Buy $34
Mar-02-20Initiated Robert W. Baird Outperform $35
Mar-02-20Initiated Morgan Stanley Overweight $34
Mar-02-20Initiated Mizuho Buy $32
Mar-02-20Initiated JP Morgan Overweight $35
Mar-02-20Initiated Jefferies Hold $30.50
Mar-02-20Initiated Goldman Buy $34
Mar-02-20Initiated Evercore ISI Outperform $33
Mar-02-20Initiated Deutsche Bank Buy $33
Mar-02-20Initiated Credit Suisse Outperform $32
Mar-02-20Initiated Citigroup Buy $34
Mar-02-20Initiated BofA/Merrill Buy $33
Mar-02-20Initiated Barclays Overweight $33
Mar-03-21 10:02AM  
Feb-26-21 10:00AM  
Feb-24-21 05:31PM  
Feb-23-21 04:05PM  
Feb-18-21 09:00AM  
Feb-17-21 10:00AM  
Feb-09-21 06:30AM  
Feb-03-21 05:10PM  
Jan-04-21 09:00AM  
Dec-28-20 06:22AM  
Dec-23-20 12:20PM  
Dec-21-20 05:25PM  
Dec-07-20 09:00AM  
Nov-02-20 10:15AM  
Oct-29-20 10:36AM  
Oct-28-20 07:00AM  
Oct-27-20 04:05PM  
Oct-26-20 08:00AM  
Oct-13-20 09:00AM  
Oct-12-20 04:05PM  
Oct-06-20 09:00AM  
Sep-30-20 09:00AM  
Sep-28-20 01:24PM  
Sep-17-20 12:00PM  
Sep-16-20 10:32PM  
Sep-14-20 04:06PM  
Sep-09-20 09:00AM  
Sep-03-20 09:00AM  
Aug-24-20 11:05AM  
Aug-20-20 07:55AM  
Aug-14-20 09:00AM  
Aug-12-20 03:11PM  
Aug-04-20 04:05PM  
Aug-03-20 09:00AM  
Jul-21-20 04:05PM  
Jul-17-20 12:00PM  
Jun-25-20 09:00AM  
Jun-04-20 09:42AM  
May-21-20 05:20PM  
May-14-20 09:00AM  
May-06-20 04:01PM  
May-01-20 04:55PM  
Apr-29-20 09:05AM  
Apr-23-20 09:00AM  
Apr-16-20 09:00AM  
Apr-02-20 09:00AM  
Mar-17-20 09:00AM  
Mar-10-20 04:01PM  
Mar-05-20 04:01PM  
Mar-04-20 04:01PM  
Mar-03-20 10:03AM  
Mar-02-20 02:31PM  
Feb-25-20 09:15AM  
Feb-20-20 09:00AM  
Feb-17-20 10:36AM  
Feb-16-20 04:07PM  
Feb-07-20 04:17PM  
Feb-06-20 04:33PM  
Feb-05-20 07:44PM  
Feb-01-20 02:34PM  
Jan-27-20 07:31AM  
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donovan GlenChief Accounting OfficerMar 03Option Exercise10.5916,347173,11519,347Mar 05 05:02 PM
Donovan GlenChief Accounting OfficerMar 03Sale35.6216,347582,2803,000Mar 05 05:02 PM
Johnston David MichaelSee RemarksMar 02Option Exercise10.5921,597228,71257,004Mar 03 04:17 PM
Garrow Ronald ESee RemarksMar 02Option Exercise17.5569,4011,217,86869,401Mar 04 05:01 PM
Garrow Ronald ESee RemarksMar 02Sale36.3869,4012,524,8080Mar 04 05:01 PM
Johnston David MichaelSee RemarksMar 02Sale36.2921,597783,75535,407Mar 03 04:17 PM
Johnston David MichaelSee RemarksMar 01Option Exercise10.5921,597228,71274,704Mar 03 04:17 PM
Johnston David MichaelSee RemarksMar 01Sale35.4339,2971,392,29335,407Mar 03 04:17 PM
SIMMONS DAVID SChief Executive OfficerFeb 12Sale38.0177,0652,929,241693,695Feb 16 05:00 PM
SIMMONS DAVID SChief Executive OfficerNov 10Option Exercise10.5930,000317,700987,759Nov 12 04:02 PM
SIMMONS DAVID SChief Executive OfficerOct 30Option Exercise10.5950,000529,500957,759Nov 03 04:43 PM
HARTMAN JUDDSee RemarksSep 29Sale34.6030,0001,038,00064,166Oct 01 05:00 PM
Kaucic KarenSee RemarksSep 29Sale34.8020,574715,9758,392Oct 01 05:00 PM
Pellegrino JillSVP & General Manager of AESSep 28Option Exercise15.052,83742,6975,495Sep 30 05:00 PM
Pellegrino JillSVP & General Manager of AESSep 28Sale34.405,495189,0280Sep 30 05:00 PM
Donovan GlenChief Accounting OfficerSep 22Sale34.762,83398,4753,000Sep 24 05:00 PM
Carlyle Group Management L.L.C10% OwnerSep 21Sale31.2810,732,261335,731,95555,722,733Sep 22 04:15 PM
Johnston David MichaelSee RemarksSep 21Sale33.1140,0001,324,40053,107Sep 23 05:01 PM
H&F Corporate Investors VIII, 10% OwnerSep 21Sale31.2824,702,175772,745,789157,138Sep 23 04:48 PM
H&F Corporate Investors VII, L10% OwnerSep 21Sale31.2824,702,175772,745,789157,138Sep 23 04:47 PM
Hill ColinDirectorSep 21Sale31.281,72253,86814,166Sep 23 04:44 PM
Garrow Ronald ESee RemarksSep 18Option Exercise14.559,500138,2259,500Sep 22 05:01 PM
Garrow Ronald ESee RemarksSep 18Sale34.129,500324,1400Sep 22 05:01 PM